MK-0616
InvestigationalAn oral macrocyclic peptide PCSK9 inhibitor in Phase 3 development by Merck. Pivotal Phase 3 LDL-C trials are now published, and the CORALreef Outcomes cardiovascular trial (~14,500 participants) is ongoing. Phase 2 data showed greater than 60% LDL-C reduction. Would be the first oral peptide-based PCSK9 drug if approved.
Merck PCSK9 Inhibitor · Oral PCSK9
8 human studies
- Preclinical
- 33%
- Clinical
- 67%
Based on 12 cited sources
clinically demonstrated · high confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 95: multiple published double-blind RCTs now exist — Phase 2b (Ballantyne 36889610, N=381, dose-dependent LDL-C reduction to -60.9%), the Phase 3 CORALreef Lipids NEJM trial (Navar 41879224, N=2,909, -55.8 pct-point LDL-C vs placebo) and the Phase 3 active-comparator CORALreef AddOn (Catapano 42017875, N=301) — plus GRADE systematic reviews/NMAs (42269009, 41690582; pooled N>4,000), giving 1A meta-analysis-of-RCTs (35), 1B low-RoB RCT + moderate-confidence review (24), 1C total N>1,000 narrow CIs (15), 1D direct population/route/LDL-C outcome but hard CV outcome still pending (13), 1E substantial preclinical program (8). Mechanism 100: PCSK9 target with ~5 pM binding, functional blockade of PCSK9-LDLR (>93% free-PCSK9 reduction; 37125593), genetically validated target, full pathway, monotonic human dose-response in vivo. Plausibility 94: mechanism->surrogate proven and surrogate->hard-outcome supported by class analogues (evolocumab/alirocumab), though enlicitide's own CV-outcome trial is pending; tightly scoped LDL-C claim. Global Coverage 73: multinational trials (US/EU/Japan/LatAm/South Africa/China) and independent unaffiliated meta-analyses replicate the finding, but the trial program is single-sponsor (Merck/MSD) and no regulator has approved it yet (4D=5). Community Experience 11: investigational, not available outside trials, negligible documented real-world use. Effectiveness basis clinical (high): LDL-C reduction ~56-65% far exceeds any LDL-C MCID and showed head-to-head superiority over ezetimibe, bempedoic acid, and their combination (42017875, all P<0.001); E3 held mid-band because LDL-C remains a surrogate pending CORALreef cardiovascular-outcome data.
How It Works (Simplified)
MK-0616 is an oral macrocyclic peptide that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, MK-0616 increases the number of LDL receptors available to clear LDL cholesterol from the blood. Unlike existing injectable PCSK9 inhibitors (evolocumab, alirocumab), MK-0616 achieves this through oral administration — a significant advance for patient adherence.
Scientific Pathways
PCSK9 Inhibition: MK-0616 binds to PCSK9 in the circulation, preventing it from binding to and degrading hepatic LDL receptors. This increases LDL receptor density on hepatocytes, enhancing LDL-C clearance from plasma.
Macrocyclic Peptide Technology: The compound uses a constrained macrocyclic peptide scaffold that provides oral bioavailability — typically a major challenge for peptide therapeutics. This technology platform could enable oral delivery of other peptide drugs.
Clinical Evidence
Phase 2 Data: A randomized, double-blind Phase 2 trial demonstrated greater than 60% reduction in LDL-C from baseline with MK-0616, comparable to injectable PCSK9 inhibitors. Results were presented at ACC (American College of Cardiology) and published in peer-reviewed journals.
CORALreef Phase 3 Program: The CORALreef cardiovascular outcomes trial (NCT06008756) enrolled approximately 14,500 patients across multiple global sites. This is one of the largest cardiovascular outcomes trials currently underway and evaluates hard cardiovascular endpoints (MACE); pivotal LDL-C-lowering trials in the program (CORALreef Lipids, AddOn, and a heterozygous familial hypercholesterolemia trial) have completed and been published.
Safety Profile
Phase 2 data showed MK-0616 was generally well tolerated with a safety profile comparable to placebo. No significant hepatic, renal, or musculoskeletal safety signals were identified. The oral route eliminates injection site reactions associated with current PCSK9 inhibitors. Full safety characterization awaits Phase 3 completion.
Important Limitations
- Pivotal Phase 3 LDL-C data published; hard cardiovascular outcomes data still pending (CORALreef Outcomes trial ongoing)
- No regulatory approval yet; no NDA filed
- Oral bioavailability of peptides can vary with food and GI conditions
- Long-term safety beyond Phase 2 duration not yet characterized
- Not available outside clinical trials
- Commercial viability depends on cost competitiveness with generic statins
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.